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Our project was designed to determine if there was a difference in vocal parameters, 
including mean fundamental frequency, mean amplitude, and total phonation time, between 
individuals diagnosed with Parkinson’s disease (PD) and age-and gender-matched individuals 
without a diagnosis of any neurologic or neurodegenerative diseases (NO PD) using the 
Ambulatory Phonation Monitor (APM: KayPENTAX, Lincoln Park, New Jersey). The APM was 
designed to gather objective data in a naturalistic environment by having participants wear the 
device over the course of three 8-hour days. The APM measured total phonation time, mean 
amplitude, and mean fundamental frequency throughout that time. The participants wore the 
APM on what they deemed “typical” days where similar routines were observed and “out of the 
ordinary” activities did not occur. Data collection was repeated three times to establish the 
reliability of the data collected. Descriptive statistics and two-way repeated measure ANOVA 
were computed using SPSS. 
NO PD group exhibited significantly higher mean amplitudes in comparison to the PD 
group. The two groups did not differ in mean fundamental frequency or phonation time. When 
asked to estimate the amount of talking time, the PD group overestimated their talk time 
significantly more than the NO PD group. These data suggest that variability of vocal parameters 
exist among individuals diagnosed with PD and age matched individuals with no diagnosis of 




 Parkinson’s disease (PD) is a progressive, neurodegenerative disease that has many 
debilitating effects on an individual’s life (NINDS, 2010; Spencer, Sanchez, McAllen, & Weir, 
2010). Motor speech deficits are included among the documented of effects of PD. Surprisingly, 
no one has attempted to use objective methods to study how these deficits may impact the 
individual’s daily speaking habits. Until recently, researchers have not been able to gather 
objective data concerning vocal parameters beyond the clinical setting. However, technology has 
presented the opportunity to do so. By using the Ambulatory Phonation Monitor (APM) Model 
3200 from KayPENTAX, data measuring vocal parameters across an extended period of time 
can be gathered. The APM was designed to inconspicuously and accurately capture a 
participant’s daily speech habits and vocal characteristics over an eight hour time span. The 
current study was designed to determine if there were differences in vocal parameters including 
mean fundamental frequency, mean amplitude, and total phonation time using the APM, between 
individuals diagnosed with PD and age- and gender-matched individuals without a diagnosis of 
any neurologic or neurodegenerative diseases. 
 This review of the literature first provides the reader with foundational information about 
PD and its effect on motor speech components, followed by review of the APM research. 
Finally, a review of the literature focusing on the vocal parameters measured by the APM (mean 
fundamental frequency, mean amplitude, and phonation time) as characteristic of PD is provided.  
Parkinson’s Disease 
 Parkinson’s disease is a progressive, neurodegenerative disease that affects the central 
nervous system (NINDS, 2010). Parkinson’s targets the substantia nigra in the basal ganglia 
leading to a degeneration of dopaminergic neurons (Spencer et al., 2010). It is estimated that in 
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the United States more than 500,000 people suffer from this debilitating disease (NINDS, 2010). 
According to the National Institute of Neurological Disorders and Stroke (2010), the average age 
of onset for PD is sixty years old. About five to ten percent of those affected by the disease have 
been diagnosed with “early-onset” PD, which is diagnosed before the age of fifty (NINDS, 
2010). Higher rates of the disease are found in males, as nearly fifty percent more men than 
women suffer from the disease (NINDS, 2010).  Interestingly, the incidence of PD is higher in 
developed countries. This is possibly due to an increased exposure to toxins (NINDS, 2010).  
 Numerous debilitating symptoms accompany PD. The symptoms most encountered 
include tremor, rigidity, bradykinesia/akinesia, and postural abnormalities (Fernandez, 
Rodriguez, Skidmore, & Okun, 2007; Spencer et al., 2010; Watts & Koller, 2004). The 
predominant symptom of PD is muscular tremor. Another symptom of PD is rigidity, a stiff 
posture of the limbs and trunk (NINDS, 2010). Rigidity causes “jerky” movements, which are 
commonly exhibited by individuals diagnosed with PD (NINDS, 2010). Slowing initiation and 
executing movements is referred to as bradykinesia (Spencer et al., 2010). Akinesia, yet another 
neuromuscular symptom of PD, refers to the lack of the ability to initiate actions (Spencer et al., 
2010). Finally, postural abnormalities or instability are characteristic of individuals with PD. 
This symptom is due to impaired balance, and is the cause of a stooped posture that is commonly 
adopted by individuals with PD (IwPD) (NINDS, 2010).  
  Secondary neurological deficits that may accompany PD include dysarthria, dysphagia, 
cognitive decline, sensory processing deficits, psychiatric disturbance, and sleep disturbances 
(Spencer et al., 2010). The most common speech deficit observed in PD is hypokinetic dysarthria 
(Duffy, 2005; Spencer et al., 2010). Characteristics of hypokinetic dysarthria include a decreased 
volume, monopitch, monoloudness, prosodic insufficiency, imprecise consonants, inappropriate 
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silences, short rushes of speech, variable rate, and repeated phonemes (Duffy, 2005; Gamboa et 
al., 1997; Spencer et al., 2010).  
Much of the research in the field of communication disorders and PD focuses on the 
reduced amplitude (perceptually called loudness) that interferes with successful communication 
(Canter, 1963; Duffy, 2005; Fox & Ramig, 1997; Ramig, Sapir, Fox, & Countryman, 2001; Scott 
& Caird, 1983; Stewart et al., 1995). Therefore therapies exist that focus on increasing vocal 
amplitude. Few studies have focused on examining fundamental frequency (perceptually called 
pitch) and total phonation time in relation to PD. Gamboa et al. (1997) noted higher mean 
fundamental frequencies in males diagnosed with PD when compared to a control group is 
comprised of 16 males and 12 women with a mean age of 67 years with a SD=6.8 years.  
Midi et al. (2008) found a higher fundamental frequency in individuals with PD compared to 
gender matched control individuals. This increase was attributed to the rigid state of the 
laryngeal muscles found in Parkinson’s sufferers (Midi et al., 2008). No literature examining a 
correlation between a diagnosis of PD and phonation time was found. 
Up to now vocal parameters (i.e. amplitude and fundamental frequency) have been 
measured in the laboratory. The results of these measures may have questionable ecological 
validity for predicting how an individual with PD will use his/her voice in everyday speaking 
situations. Objective measures that can be obtained in the client’s natural environment are 
needed before we can assess the outcome of a treatment that aims to increase vocal loudness (i.e. 





Ambulatory Phonation Monitor 
 When it comes to measuring vocal behaviors outside of the clinical setting, researchers 
often rely on subjective data supplied by the patient. However, these data rely on the client’s 
ability to self-report and self-monitor, and may not be completely accurate (Hillman, Heaton, 
Masaki, Zeitels, & Cheyne, 2006). Out of necessity for a means to collect objective data the 
Ambulatory Phonation Monitor (APM) by KayPENTAX emerged. The APM was designed for 
mobility and functionality by 1) being small enough for a person to carry or wear all day, 2) 
being light weight, and 3) having an operational battery life for 10 or more hours (Ohlsson, 
Brink, and Lofqvist, 1989). The APM allows the clinician to collect objective vocal data in a 
person’s natural environment (i.e. beyond the clinical setting).  The APM uses a small 
accelerometer sensor placed above the sternal notch. It collects data by measuring skin vibrations 
(Popolo, Svec, & Titze, 2005). The sensor is connected to the processor by a thin wire.  
There are many advantages of the accelerometer compared to a microphone. One main 
advantage of the accelerometer is that it virtually eliminates background noises compared to a 
microphone (Popolo et al., 2005). Background noise is reduced because the accelerometer 
collects data through vibrations rather than sound recordings. When background noises exceed 
80 dB speech detection decreases (Airo, Olkinuora, & Sala, 2000). Hillman et al. (2006) 
suggested that the data gathered by the accelerometer “may represent a more robust approach for 
estimating phonation parameters in disordered voices” (page 800). With use of a contact 
microphone, the exact timing of voiced speech is impossible to determine (Airo et al., 2000). 
Another benefit of the APM is that ethical questions about privacy issues that result from using a 
microphone and recorder to collect vocal data are negated (Ryu, Komiyama, Kannae, & 
Watanabe, 1983) since the accelerometer utilizes vibrations from the skin without recording 
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actual words. One could hypothesize that if an individual is not concerned with “what is being 
recorded” that he might speak more freely. However that is an empirical question at this time. 
Fundamental frequency estimations collected by the accelerometer are equivalent to those 
collected by a microphone (Hillman et al., 2006). However, several situations may lead to the 
collection of inaccurate data. The integrity of the bond between the client’s skin and the sensor 
itself should not be compromised. Data may become skewed or inaccurately measured if a gap 
forms between the two surfaces (Popolo et al., 2005). Another problem experienced while using 
an accelerometer is encountered when observing data collected on sound pressure levels (SPL). 
Svec et al. (2005) noted variability between the correlation of SPLs gathered by a microphone 
and the accelerometer estimated at + 6dB for males and + 5dB for females. 
In addition to collecting objective data for voice amplitude and fundamental frequency in 
a naturalistic way, the APM is able to gather data continuously for up to approximately 10 hours 
if needed. In the study of individuals with communication disorders, the continuous data 
collection could be useful for identification of how behaviors change over the course of a day. 
This area is ripe for research since little is known about how much individuals of any age, with 
or without neurologic disease, talk over the course of a day. In sum, the APM does allow the 
clinician or researcher to gather objective data without subjective patient-reported input, and to 
protect the privacy of the individuals.  
What follows is the state-of-the art information on known measures of the vocal 
parameters measured by the APM, amplitude and fundamental frequency. These will be used as 
comparisons for the results of this study. However, as stated above, the question about ecological 
validity has yet to be explored. Therefore we expect there may be differences in vocal parameter 
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measures when comparing normative data resulting from clinical collection to data collected in a 
naturalistic setting.  
Fundamental Frequency 
 In healthy individuals, many vocal parameters change with age. One characteristic known 
to change is fundamental frequency. Fundamental frequency is the “lowest periodic component 
of vocal fold vibration” (Kent & Read, 2002). Research has shown that fundamental frequency 
increases with age in healthy males and decreases with age in healthy females (Decoster & 
Debruyne, 1997; Higgins & Saxman, 1991; Hollien & Shipp, 1972; Nishio & Niimi, 2008; 
Russell, Penny, & Pemberton, 1995). A change in fundamental frequency has also been reported 
associated with the progression of PD within an individual (Gamboa et al., 1997; Midi et al., 
2008). 
 The significant increase in males has been observed to occur around the age of 70 
(Hollien & Shipp, 1972; Nishio & Niimi, 2008). When Hollien and Shipp (1972) compared 
fundamental frequency changes in males between decades, no significant deviation was 
measured. However, when they compared results from the 20-29 age group to the 70-79 age 
group, a drastic increase in fundamental frequency was noted. This supported the results of 
previous studies (Decoster & Debruyne, 1997; Higgins & Saxman, 1991; Hollien & Shipp, 1972; 
Nishio & Niimi, 2008; Russell, Penny, & Pemberton, 1995). Some researchers attributed this 
raise in fundamental frequency to hormonal changes (Decoster & Debruyne, 1997; Hollien & 
Shipp, 1972). It is believed that a decrease in the amount of testosterone released in the male 
body around the age of 70 is responsible for the change in fundamental frequency. Alternatively, 
Kahane (1987) attributes the increase in fundamental frequency to age dependent vocal fold 
atrophy and stiffening of the vocal tissue.  
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 Most research has conclusively shown that the decrease in fundamental frequency in 
women is due to hormonal changes around menopause (Decoster & Debruyne, 1997; Higgins & 
Saxman, 1991; Russell et al., 1995). As stated by Nishio and Niimi (2008), a much greater 
change in fundamental frequency is seen in females than in males. However, some research does 
not support the hypothesis that fundamental frequency changes with ageing in either males or 
females. For example, Ramig and Ringel (1983) found that “no significant age-related 
differences were observed in mean fundamental frequency” (page 28) in a study comparing 
voice samples of 48 males group into three different age categories (25-35, 45-55, and 65-75).  
 A change in fundamental frequency has also been reported associated with the 
progression of PD within an individual (Gamboa et al., 1997; Midi et al., 2008). A study by 
Gamboa et al. (1997) showed that males with PD treated with dopaminergic drugs exhibited a 
higher fundamental frequency when compared to matched control subjects. In 2008, Midi et al. 
conducted a study that coincides with the findings from the previously mentioned study. In the 
study by Midi et al. (2008), individuals diagnosed with PD exhibited higher fundamental 
frequency than gender matched individuals from the control group. Midi et al. (2008) suspected 
that the elevated frequency average was contributed to rigidity of the laryngeal muscular 
structures. Rigidity of the laryngeal muscles may also attribute a breathy vocal quality to persons 
diagnosed with PD (Darley, Aronson, & Brown, 1969). 
Amplitude 
 The motor speech disorder hypokinetic dysarthria is most commonly associated with PD 
(Duffy, 2005; Stewart et al., 1995). Hypokinetic dysarthria is characterized by a reduction in 
loudness or amplitude, a reduction in pitch inflection, a reduction in range of articulatory 
movements, short rushes of speech, and stuttering (Fox & Ramig, 1997; Ramig et al., 2001; Scott 
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& Caird, 1983; Stewart et al., 1995). Hypokinetic dysarthria is estimated to occur in 70-89% of 
individuals affected by PD (Darley et al., 1969; Duffy, 2005). 
A reduction in vocal intensity, or amplitude, has frequently been reported as a major 
speech deficit associated with PD (Canter, 1963). In a study by Canter (1965) individuals with 
PD “showed a reduced ability to produce “loud” and “shouted” phonations.” Fox and Ramig 
(1997) perceived this inability to produce elevated phonations as a perceptual issue. The study by 
Fox and Ramig (1997) revealed on average, individuals with PD demonstrated a reduction of 
2.0-4.0dB SPL across all speech tasks. This characteristic has been noted by family members and 
close friends of individuals afflicted by PD well before the disease has been diagnosed by a 
physician (Tetrud, 1991). Clinical observation suggests that individuals with PD may have 
impaired perception of vocal abilities. This may be related to impairment in a patient’s self-
monitoring abilities during specific motor speech tasks (Solomon, Robin, Lorell, Rodnitzky, & 
Luschei, 1994). This perceptual difference was not attributed to any form of hearing loss 
(Solomon et al., 1994).  
These findings regarding reduced vocal intensity in conjunction with PD have all been 
conducted in a clinical setting. As stated by Adams and Dykstra (2009), “Patients with PD may 
not use their habitual speech intensity levels in the unnatural context of the laboratory or speech 
clinic. Therefore, methods for obtaining acoustic measures of speech intensity outside of the 
clinical setting may need to be developed to establish valid estimates of hypophonia in PD” (p. 
169). 
Phonation Time 
 At one time, subjective reports from patients was all that researchers could rely upon 
when gathering data about an individual’s speaking habits beyond the clinical setting. Ohlsson et 
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al., (1989) found that individuals tend to overestimate the amount of talking they do in a given 
day. Little research exists that defines the average amount of speaking done by an individual 
during an entire day. This may be due to the extensive variability between individuals’ 
personalities, vocations, and educational levels for example. Ryu et al. (1983) conducted a study 
that measured speaking time for 11 individuals including a bus driver, physician, pediatric nurse, 
and clerk. The average speaking time collected was 110 minutes a day (Ryu et al.,1983). Another 
study by Watanabe, Shin, Oda, Fukaura, and Komiyama in 1987 examined speaking time in 
relation to occupation. This study averaged speaking time of twenty control subjects consisting 
of: three doctors, five nurses, four company employees, four housewives, and four medical 
students (Wantanabe et al., 1987). The mean speaking time across all occupations was 6 minutes 
and 25 seconds per hour + 1 minute and 36 seconds (Wantanabe et al., 1987). The literature 
review did not reveal any studies focusing on the difference in average speaking times for 
individuals in relation to age or specific neurologic disorders.  Our pilot data for two individuals 
with PD found an average phonation time of 11.25 minute over an average 8.25 hour time span.           
Contemporary approaches, tools, and techniques have allowed for greater flexibility in 
gathering phonation data. The APM now allows researchers to study phonation patterns by 
collecting objective data in a natural setting without having to rely on subjective patient self-
report. The capability to collect objective measures of vocal parameters in a person’s everyday 
speaking environment might serve as a valuable pre- and post-treatment treatment outcome for 
individuals with PD and dysarthria who undergo therapy to increase vocal loudness. It certainly 
appears that it provides a more ecologically valid measure of vocal parameters than those 
typically gathered in the clinic. However, there are many unknowns, which led to this study’s 




This study will focus on determining whether a difference in vocal parameters, including mean 
fundamental frequency, mean amplitude, and total phonation time, exists between individuals 
diagnosed with PD and age-and gender-matched individuals without a diagnosis of any 
neurologic or neurodegenerative diseases. The experimental questions that this study aims to 
answer are:  
1. Is there a comparable difference in mean fundamental frequency between the NO PD 
group and the PD group?  
Based on a review of the literature, it is hypothesized that participants diagnosed with 
PD will have a higher mean fundamental frequency in comparison to individuals 
without PD. 
2. Is there a comparable difference in mean amplitude between the NO PD group and 
the PD group? 
A review of the literature supports the hypothesis that participants diagnosed with PD 
will have decreased mean amplitudes compared to healthy individuals. 
3. Is there a comparable difference in total phonation time between the NO PD group 
and the PD group? 
Anecdotal evidence supports the hypothesis that participants diagnosed with PD will 





This is a prospective, between-group study on the effect a diagnosis of PD has on 
phonation time, amplitude, and fundamental frequency in comparison to age- and gender-
matched individuals using the APM to measure dependent variables. This study is defined as a 
Phase I study based on the five-phase model described by Robey (2004). “Phase I research is 
comprised of case studies, discovery-oriented single-subject studies, small group pre-post 
studies, and retrospective studies” (p. 404, Robey, 2004). Due to small sample size and frequent 
variance errors, Type I errors are allowed (Robey, 2004). This study proposal was approved by 
the Louisiana State University Institutional Review Board for the protection of human subjects 
prior to enrollment of subjects and data collection. Informed consent was collected from all 
participants. 
Subjects 
 10 community-dwelling individuals over the age of 65 years old were recruited to 
participate in this study. Two groups of 5 were created, a PD group (PD group) and a non-PD 
group (NO PD group).  Participants for the PD group in this study were recruited from the 
Louisiana State University Speech, Language, and Hearing Clinic and the Baton Rouge PD 
Support Group. The individuals must have met the following inclusion criteria: 1) a diagnosis of 
PD (as diagnosed by a neurologist), 2) no history of or evidence of neurologic or 
neurodegenerative disease other than PD, 3) a Hoehn & Yahr Rating of PD (Hoehn &Yahr, 
1967) between 1 and 3, 4) a Mini Mental State Examination (Folstein, Folstein, & McHugh, 
1975) score >24, 5) an Apathy Scale (Starkstein et al., 1992) rating <14, 6.) a Geriatric 
Depression Scale (GDS) Short Form (Sheikh & Yesavage, 1986) score of <10, and 7) 
participants had adequate hearing as determined by patient report and conversational interaction. 
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Participants for the NO PD group were recruited from the Baton Rouge/New Orleans area. The 
healthy individuals must have met the following inclusion criteria: 1) no history or evidence of 
neurologic or neurodegenerative diseases, 2) a Mini Mental State Examination (Folstein et al., 
1975) score >24, 3) an Apathy Scale (Starkstein et al., 1992) rating <14, 4) a Geriatric 
Depression Scale (GDS) Short Form (Sheikh & Yesavage, 1986) Score of <10, and 5) adequate 
hearing as determined by patient report and conversational interaction. Subjects were excluded 
from the current study based on the following criteria: (1) dementia, (2) apathy, or (3) 
depression.  
Frequently, people with PD tend to exhibit symptoms of breathiness (Adams & Dykstra, 
2009). A breathy vocal quality, which “correspond to presence of a glottal gap” (Kreiman & 
Gerratt, 2000), could affect data gathered by the APM. Kreiman, Gerratt, Precoda, and Berke 
(1992) have suggested that breathy voice quality can be assessed by comparing the amplitudes of 
the first harmonic amplitude (H1) and second harmonic (H2) of vowels. As stated by Hartl, 
Hans, Vaissiere, and Brasnu (2003), “An increase in H1-H2 has been correlated with breathy 
phonation in normal voices” (page 179). As part of the inclusion criteria, the participants were 
asked to read two sentences which were then assessed for breathiness using TF32.exe 
(Milenkovic, 2004). The H1-H2 of the same vowels were analyzed and compared to test whether 
the PD group exhibited more breathy qualities of the voice than the NO PD group. The PD group 
did not demonstrate greater ranges of H1-H2 values; therefore this group did not exhibit more 
breathy qualities in comparison to the NO PD group.  
Design 
The present prospective phase 1 study examined whether a difference existed in vocal 
parameters, including mean fundamental frequency, mean amplitude, and total phonation time, 
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between two groups, NO PD group and PD group, across an 8-hour day as measured by the 
APM. We hypothesized that there would be statistically significant differences in all three vocal 
parameters based on the literature. To test the hypotheses, we used a between-group two-way 
repeated-measures mixed design. Participants from the PD group and the NO PD group wore the 
APM for 8 hours on 3 separate days. The independent variables in this study were the inclusion 
criterion of each group: a diagnosis of PD or no diagnosis of neurologic disorders. The 
dependent variables included: mean amplitude, mean fundamental frequency, and total phonation 
time.  
Procedures 
 Calibration was completed at the LSU Communication Outcomes Research Laboratory or 
in the participant’s home. The procedures for operation of the APM-Model 3200 followed the 
manufactures (KayPENTAX) protocol. Prior to a full day’s use, standardized preparation 
protocol was followed; 1) the APM was connected to a computer, 2) a patient file was created, 3) 
the sensor was placed on the patient, 4) the APM was calibrated according to manufacturer’s 
instructions (APM: KayPENTAX, Lincoln Park, New Jersey). 
 In order to calibrate the APM to each participant’s vocal parameters, the device was 
connected to a designated microphone, with a 15 cm distance guide from the mouth to ensure a 
consistent mouth-to-microphone distance. The investigator ensured accelerometer was properly 
affixed. The APM was connected to a computer, and the green light was on, indicating that the 
APM was powered (APM: KayPENTAX, Lincoln Park, New Jersey).  
 Once the APM was connected to the microphone, computer, and the batteries were in 
place, a patient file was created. When the APM program was opened the “Select activity” box 
appears. In this box the “Configure and acquire data on the APM” selection was made. The 
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“New Patient” button was selected to input patient information and the calibration phase begun. 
Once the patient information was entered, the accelerometer sensor was attached to the patient’s 
throat. The sensor was attached to the neck at midline in the hollow area above the sternal notch 
and below the larynx using the secure adhesive glue. Once a secure bond was ensured between 
the patient’s skin and the sensor, the patient fed the wire from the sensor down his/her shirt 
exiting at the waist. This end of the wire was plugged into the APM (APM: KayPENTAX, 
Lincoln Park, New Jersey). 
 The device was calibrated to each individual in order to obtain the most accurate vocal 
parameter measures. The patient was seated facing the microphone with the distance guide place 
in between the base of the nose and the top of the upper lip. The patient was directed to sustain a 
phonation beginning softly and increasing his volume to the loudest that he/she could produce 
during the calibration process. Once the instructions were clearly stated to the patient, the 
clinician selected “Calibrate,” and the patient produced the “/a/” phonation. As the phonation 
was being produced, the program displayed dots and a straight red line representing the 
calibration of the sound pressure levels measured by the microphone and the throat sensor 
(APM: KayPENTAX, Lincoln Park, New Jersey). Once the calibration was achieved, the 










Figure 1. Example of dots and a straight red line representing the calibration of the sound 
pressure levels measured by the microphone and the throat sensor (APM: KayPENTAX, Lincoln 
Park, New Jersey). 
 
 The final step to complete the setup phase and to initiate the monitoring phase was 
disconnecting the device from the computer and microphone. The clinician selected “Start 
Monitoring” on the left-hand side of the screen, and a “Start Phonation Monitor” dialog box 
appeared. The clinician then selected “OK”, and the device light flickered green and red very 
quickly which indicated that it was in the monitoring setting. The device was then disconnected 
from the microphone and computer, and it was then placed in the waist pouch. The patient was 
given instructions to wear the device all day long, keep it safely away from water, and simply to 
disconnect the one wire running from the sensor to the APM before he/she prepared for bed. To 
remove the throat sensor, the patient was provided with an adhesive remover aid. He/she was 
instructed to lift one edge of the sensor and gently peel away from skin. He/she was also 
provided with an alcohol wipe to remove residual adhesive that may have been left on the skin. 
Finally, the patient placed the sensor in the pouch provided along with the Ambulatory 
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Phonation Monitor, which the clinician collected the following day. Once the clinician collected 
the pouch with the device, it was then plugged back into the computer used for calibration where 
the data collected was retrieved from the APM (APM: KayPENTAX, Lincoln Park, New Jersey).  
This process was completed on three separate occasions for each of the ten subjects. The 
participants wore the APM on what was deemed “typical” days where similar routines were 
observed and “out of the ordinary” activities did not take place. Data collection was repeated 
three times to establish the reliability of the data collected. A short questionnaire was provided to 
participants in order to gather data regarding comfort and use of the device. Participants were 
also provided with a time journal to document their estimated amount of phonation time. 
Participants were asked to complete the time journal by estimating their amount of phonation 
time in minutes every two hours.  
Data Analysis 
The data were gathered for each person on the three separate occasions. The information 
gathered was compared between the two groups to find deviations and patterns of correlation. 
Measured variables included phonation time, mean fundamental frequency, and mean amplitude 
(SPL). Data was collected 20 times per second throughout the time the device was worn (APM: 
KayPENTAX, Lincoln Park, New Jersey). The information was collected over an 8 hour period 
of time. Phonation time was used in this study as an index of total speaking time. 
 Results for each measure were analyzed using two-way repeated measures ANOVA’s 
with diagnoses as between subject factors and phonation variables as repeated factors. Only 
effects of diagnosis were relevant to this investigation. T-tests were conducted to determine 




To check for accuracy of data entry, dual-entry method was used in recording data into 
the data base. A second graduate student in the LSU Department of Communication Sciences 
and Disorders entered all data points gathered by the APM (n=90) into a database. The total 
percentage of agreement was calculated by dividing the total number of agreements (n=87) by 





Five participants with PD and five healthy age- and gender-matched participants were 
recruited for this study. Six males and four females participated in this study. All participants 
were Caucasian and ranged between the ages of 67 and 85. The length of diagnosis for the PD 
group ranged from 2.5 years to 8 years. MMSE (Folstein et al., 1975) scores ranged from 26 to 
30 in NO PD participants and from 27 to 30 in PD participants. Among NO PD participants, 
Apathy Scale (Starkstein et al., 1992) rating ranged from 3-13, while PD participants’ ratings 
ranged from 3 to 8. One PD patient scored 8 (10 indicates possible depression) on the Geriatric 
Depression Scale Rating (Sheikh & Yesavage, 1986), while ratings for all other participants 
ranged from 0 to 2. Table 1 shows the PD participants, along with age- and gender-matched NO 
PD individuals, as well as scores for screening for inclusion tests. The data for participant NO 
PD 03 was dropped from the analysis of mean amplitude, mean fundamental frequency, and 
phonation time due to insufficient data points. 
 Parkinson’s Participants and Healthy Matched Individuals 
 PD 01 NO 01 PD 02 NO 02 PD 03 NO 03 PD 04 NO 04 PD 05 NO 05 
Age 77 77 74 74 68 67 85 85 73 73 
Gender F F M M M M M M F F 
Years post-diagnosis  7 N/A 8 N/A 5 N/A 2.5 N/A 3 N/A 
MMSE 29 30 28 26 27 30 30 30 30 30 
H&Y Stage   2 N/A 2 N/A 2 N/A 1 N/A 1 N/A 
Apathy Scale Rating 4 3 8 3 3 13 7 3 7 4 
GDS 8 0 2 1 1 1 1 0 0 2 
Table 1. Descriptive characteristics of participants 
Note:  MMSE = Mini Mental Status Exam (Folstein et al., 1975), H&Y = Hoehn & Yahr PD 







Dual-entry method was used in recording data into the data base. A second graduate 
student entered all data points gathered by the APM (n=90) into a database. The total percentage 
of agreement was calculated by dividing the total number of agreements by the total number of 
opportunities for agreement and multiplying by 100. The two people had 97% agreement on data 
entry. 
Experimental Questions 
1. Is there a significant difference in mean fundamental frequency between the NO PD 
group and the PD group?  
Two-way repeated measures ANOVA was used to test the hypothesis that there would be 
a significant difference between the NO PD group and the PD group on mean fundamental 
frequency across three trials. Levene’s Test of Equality of Error Variances was conducted to test 
the null hypothesis that error variance of the dependent variable is equal across groups. The two 
groups have approximately equal variances during all three trials, time 1:  F(1,7) = .29, p = .60, 
time 2: F(1,7) = .46, p = .52, time 3: F(1,7) = .43, p = .53. No difference was found between the 
two groups on mean fundamental frequency across time, F(1,7) = .08, p = .78. 
To determine if there was a significant difference in mean fundamental frequency across 
time within both groups, we first examined the sphericity of the data using Mauchly’s Test of 
Sphericity. This test was not significant, W = .69, χ
2 
(2) = 2.23, p = .33, indicating that the data 
did not violate the assumption of equal variances and covariances.  This test was significant, W = 
.19, χ
2 
(2) = 9.99, p = .01, indicating that the data does not have equal variances and equal 
covariances.  Therefore, a Greenhouse-Geisser corrected F-test was used. Mean fundamental 
frequency across the measured times was not significant, F(1.11, 7.73) = 1.56, p = .25. Mean 
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fundamental frequency across the measured times within the groups was not significant, F(1.11, 
7.73) = 2.87, p = .13.  
Table 2. Group means and standard deviations for measured variables 
Dependent Variables NO PD Group Means(SD) PD Group Means(SD) 
Mean  Fundamental Frequency (Hz) 177.49 (41.49) 169.31 (39.47) 
Mean  Amplitude (dB) 81.15 (4.37) 71.24 (4.54) 




Figure 2:  Mean fundamental frequencies across the three measured times comparing results 
between the NO PD group and the PD group. 
 
2. Is there a significant difference in mean amplitude between the NO PD group and the 
PD group? 
Two-way repeated measures ANOVA was conducted to determine whether a difference 
existed between the PD and NO PD groups comparing mean amplitude during three trials. 


































error variance of the dependent variable (mean amplitude) is equal across groups. The two 
groups have approximately equal variances during each trial, time 1: F(1,7) = .17, p = .69, time 
2: F(1,7) = .03, p = .87, time 3: F(1,7) = .00, p = .97. Mean amplitude was statistically different 
among the PD group and NO PD group, F(1,7) = 17.66, p < .001. The strength of relationship 
between a diagnosis of PD and effect on mean amplitude, as assessed by η
2
, was strong, with a 
diagnosis of PD accounting for 72% of the variance of the dependent variable.  
To determine if mean amplitude was significantly different across time within both 
groups, we first examined the sphericity of the data using Mauchly’s Test of Sphericity. This test 
was significant, W = .35, χ
2 
(2) = 6.37, p = .04, indicating that the data do not have equal 
variances and equal covariances. Therefore, a Greenhouse-Geisser corrected F-test was used. 
Mean amplitude across the measured times was not significant, F(1.21, 8.46) = .75, p = .44. 
Mean amplitude across the measured times within the groups was not significant, F(1.21, 8.46) = 
2.06, p = .19. There was a significant difference between the two groups on mean amplitude with 
the NO PD group having a higher mean amplitude (M = 81.16, SD = 4.37) than the PD group (M 
= 71.24, SD = 4.54). Within each group, mean amplitude remained relatively stable. Refer above 




Figure 3. Mean amplitudes across the three measured times comparing results of the PD group 
and NO PD group. 
 
3. Is there a significant difference in total phonation time between the NO PD group and 
the PD group? 
Two-way repeated measures ANOVA was conducted to compare the difference between 
the two group’s phonation times during three trials. The Levene’s Test of Equality of Error 
Variances was conducted to test the null hypothesis that the error variance of the dependent 
variable is equal across groups. The two groups have approximately equal variances during each 
trial, time 1:  F(1,7) = .2.67, p = .15, time 2: F(1,7) = 1.97, p = .20, time 3: F(1,7) = 4.84, p = .06. 
Neither a PD diagnosis nor a NO PD diagnosis have an effect on phonation time, F(1,7) = 1.40, 
p = .28. 
To determine if there was a significant difference in fundamental frequency across time 
within both groups, we first examined the sphericity of the data using Mauchly’s Test of 
Sphericity. This test was not significant, W = .95, χ
2 
(2) = .30, p = .86, indicating that the data do 


































to be corrected. Phonation time across the measured times was not significantly different, 
F(2,14) = .75, p = .49. Phonation time across the measured times within the groups was not 




Figure 4.  Phonation time across the three measured times comparing results of the PD group and 
NO PD group. 
 
A paired-samples t test was conducted to determine if actual phonation time differed 
from self estimated phonation time among NO PD individuals. Results indicated that the mean 
for the actual phonation time (M = 51.09, SD = 34.48) was not significantly different than the 
mean for self-estimated phonation time (M = 99.72, SD = 87.09), t(12) = -1.97, p = .07.  
Similarly, a paired-samples t test was conducted to determine if the PD group’s actual 
phonation time differed from its self-estimated phonation time. Results indicated that the mean 

































mean for the actual phonation time (M = 32.15, SD = 15.27), t(13) = -5.63, p = .00. The PD 




 A number of studies have shown that PD may affect fundamental frequency (Gamboa et 
al., 1997; Midi et al., 2008) and amplitude (Fox & Ramig, 1997; Ramig et al., 2001; Scott & 
Caird, 1983; Stewart et al., 1995). However, no research has ever studied total phonation time of 
older adults with or without PD. This study attempted to determine if there was a difference in 
vocal parameters including mean fundamental frequency, mean amplitude, and total phonation 
time using the APM, between individuals diagnosed with PD and age- and gender-matched 
individuals without a neurologic or neurodegenerative disease. The ultimate goal of this project 
was to determine if it was feasible to use the APM to gather objective data on the vocal 
parameters of older participants with and without PD beyond the clinical setting, and to begin to 
collect normative data on talk time among older people.   
Mean fundamental frequency refers to the average of the “lowest periodic component of 
vocal fold vibrations” (Kent and Reed, 2002). We used the APM to measure mean fundamental 
frequency and to determine whether a significant difference existed between the two groups. 
Results showed that mean fundamental frequencies of the NO PD and PD groups did not differ 
significantly. Although, the literature suggests that the progression of PD affects a patient’s 
fundamental frequency (Gamboa et al., 1997; Midi et al., 2008) this study failed to reject the null 
hypothesis that the PD group did not have a higher mean fundamental frequency compared to the 
NO PD group.   One possible reason we found no difference in mean fundamental frequency 
could be attributed to the fact that all participants of the PD group had a Hoehn & Yahr PD Stage 
(Hoehn & Yahr, 1967) of 1-2. A higher mean fundamental frequency may be more pronounced 
as the severity of the disease progresses.  
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 Reduced vocal intensity, or amplitude, has frequently been reported as a major speech 
deficit associated with PD (Canter, 1963; Duffy 2005; Fox & Ramig, 1997; Scott & Caird, 1983; 
Stewart et al., 1995; Ramig et al., 2001). Our results suggested that there was a significant 
difference between the mean amplitude of the two groups. The NO PD group exhibited 
significantly greater mean amplitudes than individuals in the PD group. This is consistent with 
the research published by Canter (1963 & 1965) and Fox and Ramig (1997). Interestingly, Fox 
and Ramig (1997) suggest that the inability to produce elevated phonations was due to perceptual 
deficits resulting from PD. Although a diagnosis of PD affected mean amplitude between groups, 
within both groups variation was similar. These patterns suggest that participants diagnosed with 
PD exhibited lower mean amplitudes outside of the clinical setting, although all had participated 
in speech therapy at some point since their diagnosis.   
We recognize that a variation in amplitude may exist when measured by an accelerometer 
in comparison to a microphone (Svec et al., 2005). This may have had an effect when 
considering the average amplitude reduction associated with PD is only +2-4 dB (Fox & Ramig, 
1997). However, because we were not making comparisons between data collected by 
microphone and APM data, we do not feel the finding had an effect on our results.   
Finally, we asked whether a significant difference in total phonation time between the 
NO PD group and the PD group existed. Our data showed that total phonation time was not 
significantly different between the two groups. Although, the mean length of 53.14 minutes for 
the NO PD group and 33.18 minutes for the PD group seemed short on first inspection. Results 
also showed that phonation time was similar within groups as well.   The data collected in this 
study for the NO PD group were comparable to those found in a study by Wantanabe et al. 
(1987) who spoke an average of 6 minutes and 25 seconds per hour + 1 minute and 36 seconds. 
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However both groups exhibited notably less phonation time compared to the participants of the 
study by Ryu et al. (1983) who spoke an average of 110 minutes a day. 
To see how well participants were able to estimate their talking time while wearing the 
APM, each participant completed a “Time Journal” wherein they estimated how many minutes 
they spoke every two hours (APPENDIX A). No statistically significant results were found 
within the NO PD group. However, results for the PD group revealed that estimated talk time 
was statistically higher than APM-recorded total talk time. Thus the PD group thought they 
talked more than they did. This behavior seems to be consistent with the literature showing that 
people with PD overestimate their ability in self-report measures (Donovan, 2008). Moreover, 
this result might suggest that participants with PD may have impaired time management abilities, 
a frontal executive function.  This would conform to the research findings that individuals with 
PD misjudge functional difficulties (Marsden, Parkes, & Quinn, 1981; Yorkston et al., 1994; 
Yorkston et al., 2004) because of executive function deficits (Ho et al., 2002). Dopaminergic 
cells depletion of the frontal cortex and mesocortical dogaminergic system deterioration is 
characteristic of PD, which is believed to influence executive function skills (Owen, 2004). 
People with PD have also overestimated loudness (Fox & Ramig, 1997), a perceptual skill. 
Therefore questions remain about whether this finding of overestimation in PD is related to 
decreased insight, or perceptual deficits.  
Along with the “Time Journal,” the study’s participants were asked to complete a 
questionnaire regarding the comfort of wearing the APM (APPENDIX B). The questionnaire 
asked them to rate comfort wearing the device in general, wearing it in public, comfort while 
speaking with the device on, and other questions regarding whether or not they felt the device 
affected their speech output. When asked if the APM was a comfortable device to wear in 
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general on a scale of 1-5 (1being very uncomfortable and 5 being very comfortable), the 
participants gave it an average rating of 3.82. The participants rated their comfort in public as 
4.67 out of 5. When asked if the participants were comfortable speaking while wearing the APM, 
the participants gave it an average rating of 4.86. In an attempt to add a measure of validity to the 
study, Question 4 asked the participants if they felt that the APM measured a “normal” day of 
speech for them. 89% of participants felt that the APM measured a typical day of speech. 82% of 
the participants reported that they spoke the same amount as usual, 11% felt they spoke less than 
usual, and 7% felt they spoke more than usual. 93% of the participants reported that the APM did 
not affect his/her speech in anyway. Of interest, the 7% who reported that the APM affected their 
speech were in the PD group. These participants commented that the APM reminded them to use 
techniques learned in previous speech therapy sessions. In this study, the APM may have served 
as an external cue for the PD group to speak louder. If that is the case, we suggest that the 
difference in mean amplitudes between groups might have been even greater. 
Limitations 
 There were a number of limiting factors encountered during the study.  One limitation 
may have been the small sample size.  The results indicated considerable variation on all vocal 
parameters both among and between participants, although they met the statistical assumptions 
needed to perform ANOVA. A larger sample size may have decreased the variability, and 
resulted in different findings. Another limitation may have had to do with the durability of the 
device.  The APM was developed in a clinical setting and may not have been intended for the 
rigors of everyday wear and tear that it was given by the participants in this study. Although the 
PI applied the accelerometer each morning, individuals removed it at night.  At one point late in 
the study, the wire leading to the accelerometer tore, rendering the device inoperable. We suspect 
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that although participants were trained in the careful detachment of the accelerometer at the end 
of the day, they may have pulled on the wire leads which resulted in tearing. We should note that 
the manufacturer was extremely helpful in replacing the damaged equipment so that the study 
did not have to be discontinued or suffer from a prolonged hiatus.   
The most common complaint voiced by the participants of this study had to do with APM 
design. Participants suggested a smaller model or less bulky model would be better for 
portability and day-long wear. This might allow participants to be less aware of the device and 
possibly enter into more interactions. As mentioned above, the APM seemed to make some 
participants more aware of their speech throughout the day. Comments from 3 of the 5 PD group 
participants suggested that the APM served as an external cue, thus reminding them to use 
techniques they had learned in speech therapy to speak louder. Taking this into consideration, the 
finding of increased amplitude for PD participants is of interest because none of the participants 
of the NO PD group reported that the APM made them aware of their speaking patterns. Larger 
patterns of difference may have resulted between group had the APM not reminded the 
participants to speak louder.  
Future Studies 
 While this study utilized a Phase I design, and a small sample size, we feel that these 
results justify further research on the viability of using the APM as a treatment outcome measure 
in participants’ natural speaking environments. Future studies using larger sample size could 
establish normative phonation time for older adults with and without PD. A study could expand 
to capture middle age or young adults as well. This normative information could provide 
direction for treatment goals and daily planning.  Along other lines, individuals with PD 
significantly overestimated their phonation time when the “Time Journal” was compared to 
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results of the APM. Given the literature that describes frontal executive function deficits in PD, 





 This is the first study of its kind to examine the difference in vocal parameters between 
individuals diagnosed with PD and age-and gender-matched individuals without a diagnosis of 
any neurologic or neurodegenerative diseases using an objective measure in a naturalistic setting.   
Although our findings are preliminary, they lead us to believe that the area is ripe for study and 
the results could benefit add to understanding more about the vocal behaviors of both healthy, 
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APPENDIX A: TIME JOURNAL 
 
Ambulatory Phonation Monitor 




Hours 1-2 (9:00-11:00)________________________ 
 
 
Hours 3-4 (11:00-1:00)________________________ 
 
 
Hours 5-6 (1:00-3:00)_________________________ 
 
 






APPENDIX B: QUESTIONNAIRE 
 
 
Ambulatory Phonation Monitor 
 
1. Was the Ambulatory Phonation Monitor a comfortable device to wear? (1=not very 
comfortable; 5= very comfortable) 
1  2  3  4  5 
 
2. How comfortable were you wearing the Ambulatory Phonation Monitor in public? 
1  2  3  4  5 
 
3. Did you feel comfortable speaking while wearing the Ambulatory Phonation Monitor? 
1  2  3  4  5 
 
4. Do you feel that it measured a “normal” day of speech for you? 
Yes    No 
 
5. Do you feel that you spoke more, less, or the same amount as you usually speak in a 
typical day while wearing the Ambulatory Phonation Monitor? 
More   Less   Same 
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